Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.48 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.48 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | PAM | P19021 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2043779 | 1.00 | HSD11B1 (0.50) | HSD11B1GRIK1GRIK2TNFRSF1ANFE2L2 | |
| SCHEMBL727447 | 1.00 | HSD11B1 (0.50) | HSD11B1GRIK1GRIK2TNFRSF1ANFE2L2 | |
| SCHEMBL9065856 | 0.88 | TBXAS1 (0.56) | HSD11B1FFAR1ALDH1A1MAPTCYP19A1 | |
| SCHEMBL9065858 | 0.88 | TBXAS1 (0.56) | HSD11B1FFAR1ALDH1A1MAPTCYP19A1 | |
| SCHEMBL1006878 | 0.86 | TBXAS1 (0.55) | FFAR1ALDH1A1MAPTCYP19A1PPARG | |
| SCHEMBL1006879 | 0.86 | TBXAS1 (0.55) | FFAR1ALDH1A1MAPTCYP19A1PPARG | |
| SCHEMBL10988837 | 0.85 | TBXAS1 (0.47) | HSD11B1GRIK1GRIK2TNFRSF1AFFAR1 | |
| SCHEMBL10988834 | 0.85 | TBXAS1 (0.47) | HSD11B1GRIK1GRIK2TNFRSF1AFFAR1 | |
| SCHEMBL10988831 | 0.85 | TBXAS1 (0.47) | HSD11B1GRIK1GRIK2TNFRSF1AFFAR1 | |
| SCHEMBL18598225 | 0.84 | HSD11B1 (0.53) | HSD11B1GRIK1GRIK2TNFRSF1ANFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2326616-B1 | PROCESS FOR THE SYNTHESIS OF EZETIMIBE AND INTERMEDIATES USEFUL THEREFORE | LEK PHARMACEUTICALS (SI) | 2017-03-08 | — | — | EP | claimed |
| JP-2011529473-A | — | — | 2011-12-08 | — | — | JP | claimed |
| US-20110183956-A1 | PROCESS FOR THE SYNTHESIS OF EZETIMIBE AND INTERMEDIATES USEFUL THEREFOR | LEK PHARMACEUTICALS D.D. (SI) | 2011-07-28 | — | — | US | claimed |
| EP-2326616-A1 | PROCESS FOR THE SYNTHESIS OF EZETIMIBE AND INTERMEDIATES USEFUL THEREFOR | LEK Pharmaceuticals d.d. (SI) | 2011-06-01 | — | — | EP | claimed |
| WO-2010012775-A1 | PROCESS FOR THE SYNTHESIS OF EZETIMIBE AND INTERMEDIATES USEFUL THEREFOR | LEK PHARMACEUTICALS D.D. (SI) | 2010-02-04 | — | — | WO | claimed |
| EP-2149547-A1 | Process for the synthesis of ezetimibe and intermediates useful therefor | LEK Pharmaceuticals D.D. (SI) | 2010-02-03 | — | — | EP | claimed |
| CN-104860980-B | It is a kind of to be used to synthesize intermediate of Ezetimibe and its preparation method and application | 上海弈柯莱生物医药科技有限公司 | 2018-06-19 | — | — | CN | disclosed |
| EP-2326616-B1 | PROCESS FOR THE SYNTHESIS OF EZETIMIBE AND INTERMEDIATES USEFUL THEREFORE | LEK PHARMACEUTICALS (SI) | 2017-03-08 | — | — | EP | disclosed |
| CN-104072398-B | A kind of method of synthesizing Ezetimibe | Henan Academy of SciencesChemistry Institute Co., Ltd. (CN) | 2016-02-03 | — | — | CN | disclosed |
| CN-104860980-A | Ezetimibe synthesis intermediate and preparation method and application thereof | NANJING ABIOCHEM BIOMEDICAL TECHNOLOGY CO LTD | 2015-08-26 | — | — | CN | disclosed |
| CN-104072398-A | Method for synthesizing ezetimibe | INST CHEMISTRY CO LTD HENAN ACADEMY OF SCIENCES | 2014-10-01 | — | — | CN | disclosed |
| CN-102112430-B | Process for synthesis of ezetimibe and intermediates useful therefor | LEK PHARMACEUTICALS | 2014-05-28 | — | — | CN | disclosed |
| CN-102477008-B | Method for synthesizing ezetimibe | UNIV SHENYANG PHARMACEUTICAL | 2014-05-21 | — | — | CN | disclosed |
| EP-2149547-A1 | Process for the synthesis of ezetimibe and intermediates useful therefor | LEK Pharmaceuticals D.D. (SI) | 2010-02-03 | — | — | EP | disclosed |
| EP-2149547-A1 | Process for the synthesis of ezetimibe and intermediates useful therefor | LEK Pharmaceuticals D.D. (SI) | 2010-02-03 | — | — | EP | disclosed |
| WO-2009140932-A2 | METHOD OF PRODUCING (3R,4S)-L-(4-FLUOROPHENYL)-3-[(3S)-3-(4-FLUOROPHENYL)- HYDROXYPROPYL)]-4-(4-HYDROXYPHENYL)-2-AZETIDINONE | ZENTIVA, K.S. (CZ) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009106021-A1 | INTERMEDIATES FOR THE PREPARATION OF (3R, 4S) -1- (4-FLUOROPHENYL) -3- [ (3S) -3- (4-FLUOROPHENYL) -3-HYDROXYPROPYL) ] -4- (4-HYDROXYPHENYL) -2-AZETIDINONE | ZENTIVA, K.S. (CZ) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009067960-A2 | A METHOD OF MANUFACTURING (3R,4S)-L-(4-FLUOROPHENYL)-3-[(3S)-3-(4-FLUOROPHENYL)-3- HYDROXYPROPYL)]-4-(4-HYDROXYPHENYL)-2-AZETIDINONE AND ITS INTERMEDIATES | ZENTIVA, A.S. (CZ) | 2009-06-04 | — | — | WO | disclosed |
| WO-2008106900-A1 | METHOD OF MANUFACTURING (3R, 4S) -1- (4-FLUOROPHENYL) -3- [ (3S) -3- (4 -FLUOROPHENYL) -3-HYDROXYPROPYL) ] -4- (4-HYD ROXYPHENYL) -2-AZETIDINONE | ZENTIVA, A.S. (CZ) | 2008-09-12 | — | — | WO | disclosed |
| EP-0298466-A2 | Substituted alkene carboxylic acid amides and derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1989-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183956-A1 | PROCESS FOR THE SYNTHESIS OF EZETIMIBE AND INTERMEDIATES USEFUL THEREFOR | FAR1, SOAT1, SOAT2 | HSD11B1 111/4885GRIK1 2921/4885GRIK2 3299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.